This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in US$ Million by the following growth factor types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 90 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Johnson & Johnson, Janssen, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Table of Contents
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Blood Growth Factors
Erythropoietins
Colony Stimulating Factors
Interferons
Interleukins
Tissue Growth Factors
II. EXECUTIVE SUMMARY
1. INTRODUCTION
Growth Factors: A Preface
Growth Factors: Their Role and Related Applications
Growth Factors: Adding a New Dimension
Growth Factors: Classification Based on Activity
Recent Trends & Developments
Recombinant Human Erythropoietin: Gradually Gaining Dominance
Leading EPO Drugs Worldwide
Market Comparison of Erythropoietin-Based Drugs in America and European Union
Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007
Patent Expiries of Biopharmaceuticals in Developed Regions - Europe and United States
2. MARKET DYNAMICS
Major Companies Impacted by Patent Expiries
Patent Expiries Fuel Competition and Sales
Side Effects - Still a Concern
CDER- A Regulatory Review Authority for Growth Factors
Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors
Cytokines- Vital Growth Propellers for the Future of New Drugs
Development of Cost Effective Methods - Need of the Hour
Influence of Neurotrophic Factors on Brain Cell Development
Combination of Interferons and Ribavirin Develops More Anemia Cases
4. GROWTH FACTORS - AN OVERVIEW
Blood Growth Factors
Erythropoietins
Types of Erythropoietins
Epoetin
Darbepoetin
Aranesp(r)
Aranesp Vs. Other EPOs
Recombinant Human EPO (rHuEPO)
Colony Stimulating Factors
Granulocyte-Colony Stimulating Factor
Granulocyte Macrophage-Colony Stimulating Factor
Other Colony Stimulating Factors
Macrophage Colony Stimulating Factor (M-CSF)
Key Functions of M-CSF
Side-Effects of Colony-Stimulating Factors
Interferons
Types of Interferons
Interferon-gamma
1a and 1b: Two Key Biochemical Forms of Interferon-ƒÀ
PEG-Intron
Types of Interferons
Interleukins
Types of Interleukins
Tissue Growth Factors
Wound Healing Growth Factors
Neurotrophic Growth Factors
Nerve Growth Factor
Vascular Endothelial Growth Factor (VEGF)
Fibroblast Growth Factor (FGF)
Insulin-Like Growth Factor-I (IGF-I)
Insulin-Like Growth Factor-II (IGF-II)
Tissue Growth Factors: Classification Based on Key Source and Principal Activity
Platelet - Derived Growth Factors in Wound Healing
Thrombopoietin (TPO)
Growth Factors: Their Mode of Action in Tissue Repair
Angiogenesis: Their Role in Wound Healing
Angiogenesis As an Alternative for Cardiac Stents
Applications of Growth Factors
Growth Factors: Site/Course of Action and Applications
5. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST REVIEW
Maxygen Updates on Factor VII Program
Evaluation of Extended Dosing Schedule of PROCRIT(r)
PROCRIT(r) - A Better Option
Nerve Growth Factor Shows Promising Potential Against Diabetes
Cytokines and GM-CSF Found to be Closely Interlinked
GM-CSF Enhances Rate of Survival in Neonates
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients
rG-CSF- Their Influence on Preterm Infants with Sepsis
Serum Macrophage Colony Stimulating Growth Factors Associated with Thrombocyte and Monocyte
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and Proliferation
Cole Eye Institute Offers TIMP-3 Mechanism for Preventing Abnormal Growth of Blood Vessels
Effect of Brain Derived Neurotrophic Factor on Retinal Cells
Orcel(tm) Exhibits High Growth Factor for Wound Healing and Cardiovascular Applications
Drug Combination of Macrophage Colony Stimulating Factor Shows Successful Tolerance Levels
Neotrofin(tm) Triggers Neurotrophic Factors
G-CSF Shows Capability for Promoting Neutrophil Production
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates Wound Healing Process
Hepatocyte Growth Factors - Exhibiting Dual Role
Cortex Pharmaceuticals Ampakines(r) Promotes Expression of Neurotrophin
Granulocyte Colony Stimulating Factor Finds Application in Treating Neonates
Cerebrolysin Promotes Cognition
6. BREAKTHROUGHS - A RECENT PAST REVIEW
Novel Set of Human Cytokines Unveiled
IGFBP-3 and its Potential to Ward Off Gastric Cancer
Bone Morphogenic Proteins Show Potential for Musculoskeletal Regeneration
Growth Factors - Their Role in Preventing Heart Stroke
Growth Factor Proteins Show Promising Results for Treating Cancer
Neurotrophic Growth Factor - Primarily Responsible for Loss of Vision
Redox-Active Grape Seed Exhibits Favorable Properties for Dermal Wound Healing
Role of Brain-Derived Neurotrophic Factor on Memory
Nerve Growth Factor Found to Enhance Barium Current and Insulin Secretion
Lipid Peroxidation May be Associated with Wound Healing
Genentech Inc Unveils Molecule for Stimulating Growth of Blood Vessels
Connective Tissue Growth Factor Found to Promote Lung Fibroblast
Influence of Insulin-Like Growth Factor on Growth
Regeneron Discovers Angiopoietins Targeted at Blood Vessel Growth and Repair
Environment and Insulin-Like Growth Factors Stimulate Risk of Cancer
Cocktail of Neurotrophic Factors Promotes Regeneration of Torn Nerves
Growth Factors Administration to Stimulate Tissue Repair
Cytokine - Their Role in Combating Hepatitis C Virus
Axokine(r) Yields Favorable Results Against Obesity
Cell Genesys Unveils GDNF Gene Therapy Targeted Against Parkinson's Disease
7. PRODUCT INTRODUCTIONS/INNOVATIONS
Sandoz Unveils Zarzio
Wockhardt Launches Three Biotechnology Products
Extavia(r) Receives Approval from European Commission
Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric Patients
Hospira Receives EC Approval on Retacrit
Tercica Receives FDA Approval For Increlex
Ventria Bioscience Introduces Lacromin
Dragon Pharmaceuticals Bags Market Approval from Chinese SDA
DPI Receives Approvals for Erythropoietin in Three New Markets
Wockhardt Introduces Wepox Recombinant Erythropoietin Drug
Shanta Biotechnics Unveils Shanferon
SkinMedica Unveils TNS Recovery Complex(tm) Gel
CellGenix Unveils Cytokines for Cell Applications
Cel-Sci Corporation Develops Multikine
Wockhardt Limited Unveils EPOX(tm)
8. RECENT INDUSTRY ACTIVITY
Soluble Systems Collaborates with LifeNet Health's Subsidiary to Introduce TheraSkin(tm)
GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership
Sanofi Takes Over Shantha Biotech
Kaken Pharmaceutical Enters into Licensing Agreement with Olympus Corporation
9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER
Biovitrum and Amgen Sign Agreement
Merck Establishes Production Unit
Eli Lilly and Company Acquires ImClone Systems
GeneMedix Changes Name to Reliance GeneMedix
FDA Approves Label Expansion for VIDAZA
Pfizer Inks Exclusive Global Licensing Agreement with Scil Technology
ZGEN Initiates Ph II Trial of Interleukin 21
FzioMed Bags Health Canada Approval on Oxiplex(r)
NsGene A/S Implants Encapsulated Cell in Patients
Reliance Life Sciences Takes Over Genemedix
Fraunhofer Institute Introduces First Interferon Beta 1a to Treat Multiple Sclerosis
Shanghai Wanxing Inks Export Deal for Recombinant Human Interferon
Hemispherx Enters into Distribution Agreement with Armada
Bayer Establishes US Pharmaceuticals Subsidiary
Merck Inks Agreement with Bristol-Myers Squibb and ImClone
CoGenesys Signs Global Licensing Agreement with Vegenics
InterMune Inks New Supply Deal with Boehringer Ingelheim
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals
Cambrex Divests Bioproducts and Biopharma Subsidiaries
Dragon Divests EPO Business
Caregene and Genzyme Forms Partnership to Develop Cere-120
NsGene to Undertake Phase Ib Clinical Trial of NsG0202
Roche Receives European approval for NeoRecormon
Bolder Receives Two U.S. Patents for Hematopoietic Factors
RLS to Initiate Clinical Trials of Erythropoietin
InterMune Drops Phase III trial of Interferon
Chugai to Conduct Additional Trial on Epogin(r)
Merck KGaA Acquires Serono Labs
CytoPharm Acquires Low-Dose Interferon License from Amarillo Biosciences
Hospira Signs Agreements with STADA and BIOCEUTICALS for Erythropoietin
Biocon Bags GEAC Approval to Conduct Clinical Trial of Granulocyte Colony Stimulating Factor
SII to Conduct Clinical Trials of Rdna Products
Claris to Construct Production Facility for EOP
Mayne and Pliva to End Collaboration on Erythropoietin Development
GeneMedix Collaborates with CJ Corp.
FzioMed and USC Enter into Licensing Agreement for Oligopeptides
AnGes MG Enters Into An Agreement with Vical
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA
Dragon Pharmaceuticals Acquires Oriental Wave
Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series
Amrad and Ludwig Institute Jointly Focus on the Development of VEGF-B
GeneMedix Restructures Business
pSivida Limited Collaborates with Ian Wark Research Institute
Amgen Acquires Tularik
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S(tm)
Chugai and Roche Expand Drug Research Synergies
Dragon Pharmaceuticals to Construct New Production Facility
FibroGen Signs Contract with Yamanouchi for Licensing EPO Small Molecule
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine
Maxygen and Rentschler Enter into a Contract for G-CSF
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta Interferon
Dragon Pharmaceuticals Signs Agreement with Zhongkai
Dragon Pharmaceuticals Enters into Definitive Agreement with Oriental Wave
Zymogenetics Bags US FDA Clearance
Ceregene Bags Patent
10. FOCUS ON SELECT GLOBAL PLAYERS
Alseres Pharmaceuticals, Inc. (USA)
Amgen, Inc. (USA)
Bayer HealthCare Pharmaceuticals, Inc. (USA)
BioMimetic Therapeutics, Inc. (USA)
Biopharm GmbH (Germany)
Bolder Biotechnology, Inc. (USA)
Ceregene, Inc. (USA)
FibroGen, Inc. (USA)
FzioMed, Inc. (USA)
Genzyme Corporation (USA)
Novo Nordisk A/S (Denmark)
Reliance GeneMedix Plc. (UK)
Johnson & Johnson (USA)
Janssen, Inc. (Canada)
Lonza Group (Switzerland)
Maxygen, Inc. (USA)
Merck Serono International S.A. (Switzerland)
NsGene A/S (Denmark)
PeproTech, Inc. (USA)
Rentschler Biotechnologie GmbH (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Chugai Pharmaceutical Co. Ltd. (Japan)
Genentech, Inc. (USA)
Shantha Biotechnics (India)
Scil Proteins GmbH (Germany)
Wockhardt Ltd. (India)
11. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 2: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 3: World 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 4: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 5: World Historic Review for Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 003 through 2008 (includes corresponding Graph/Chart)
Table 6: World 15-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
Table 7: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 8: World Historic Review for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 9: World 15-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 10: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 11: World Historic Review for Erythropoietins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 12: World 15-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
Table 13: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 14: World Historic Review for Colony Stimulating Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 15: World 15-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 17: World Historic Review for Interferons as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 18: World 15-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 20: World Historic Review for Interleukins as Blood Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Table 22: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
Table 23: World Historic Review for Tissue Growth Factors by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 24: World 15-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
Leading EPO Drugs in the US
B. Market Analytics
Table 25: The US Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 26: The US Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 27: The US 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
2. JAPAN
A. Market Analysis
Erythropoietin Market
Leading EPO Drugs in Japan
Market Scenario for Biotech Products
Biotech Market Backed by Public Assistance
B. Market Analytics
Table 28: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 29: Japanese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 30: Japanese 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
3. EUROPE
A. Market Analysis
Erythropoietin Market
Leading EPO Drugs in Europe
B. Market Analytics
Table 31: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 32: European Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 33: European 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
4. REST OF WORLD
A. Market Analysis
An Overview of Indian Market
Erythropoietin
G-CSF Market
Interferon
B. Market Analytics
Table 34: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 35: Rest of World Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 36: Rest of World 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
Growth Factors (Blood And Tissue) published by Global Industry Analysts, Inc. in May 1, 2012. This report consists of Pages: 579 and the price starts from US $ 4500.
The contents of this page may be different from the latest version. Please contact us for details.
